TWI736660B - 包含Akt蛋白質激酶抑制劑之醫藥組合物 - Google Patents

包含Akt蛋白質激酶抑制劑之醫藥組合物 Download PDF

Info

Publication number
TWI736660B
TWI736660B TW106126958A TW106126958A TWI736660B TW I736660 B TWI736660 B TW I736660B TW 106126958 A TW106126958 A TW 106126958A TW 106126958 A TW106126958 A TW 106126958A TW I736660 B TWI736660 B TW I736660B
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
weight
monohydrochloride
present
specific embodiment
Prior art date
Application number
TW106126958A
Other languages
English (en)
Chinese (zh)
Other versions
TW201808337A (zh
Inventor
雷恩哈得 倫茲
波明 席得伯
安德魯 黑爾
彼得 史迪鐸
馬汀 汪德利奇
瑪麗 比伯恩傑克
法蘭西斯 勾賽琳
愛德華 悠斯特
Original Assignee
瑞士商赫孚孟拉羅股份公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 瑞士商赫孚孟拉羅股份公司 filed Critical 瑞士商赫孚孟拉羅股份公司
Publication of TW201808337A publication Critical patent/TW201808337A/zh
Application granted granted Critical
Publication of TWI736660B publication Critical patent/TWI736660B/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/005—Coating of tablets or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J3/00—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms
    • A61J3/10—Devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms into the form of compressed tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2059—Starch, including chemically or physically modified derivatives; Amylose; Amylopectin; Dextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Inorganic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TW106126958A 2016-08-10 2017-08-09 包含Akt蛋白質激酶抑制劑之醫藥組合物 TWI736660B (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201662373252P 2016-08-10 2016-08-10
US62/373,252 2016-08-10

Publications (2)

Publication Number Publication Date
TW201808337A TW201808337A (zh) 2018-03-16
TWI736660B true TWI736660B (zh) 2021-08-21

Family

ID=59569321

Family Applications (3)

Application Number Title Priority Date Filing Date
TW106126958A TWI736660B (zh) 2016-08-10 2017-08-09 包含Akt蛋白質激酶抑制劑之醫藥組合物
TW111136403A TW202329972A (zh) 2016-08-10 2017-08-09 包含Ａｋｔ蛋白質激酶抑制劑之醫藥組合物
TW110124994A TWI777658B (zh) 2016-08-10 2017-08-09 包含Akt蛋白質激酶抑制劑之醫藥組合物

Family Applications After (2)

Application Number Title Priority Date Filing Date
TW111136403A TW202329972A (zh) 2016-08-10 2017-08-09 包含Ａｋｔ蛋白質激酶抑制劑之醫藥組合物
TW110124994A TWI777658B (zh) 2016-08-10 2017-08-09 包含Akt蛋白質激酶抑制劑之醫藥組合物

Country Status (12)

Country Link
US (2) US11337977B2 (ja)
EP (1) EP3496722A1 (ja)
JP (3) JP6875501B2 (ja)
KR (3) KR102281695B1 (ja)
CN (3) CN109789141B (ja)
AU (3) AU2017310454B2 (ja)
BR (1) BR112019002007B1 (ja)
CA (1) CA3032233C (ja)
IL (3) IL264593B (ja)
MX (2) MX2019001579A (ja)
TW (3) TWI736660B (ja)
WO (1) WO2018029226A1 (ja)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6875501B2 (ja) 2016-08-10 2021-05-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ａｋｔプロテインキナーゼ阻害剤を含む薬学的組成物
CA3099888A1 (en) * 2018-07-27 2020-01-30 Sandoz Ag Process for preparing rapidly or very rapidly dissolving tablets comprising freely soluble api
EP4003309A1 (en) * 2019-07-31 2022-06-01 F. Hoffmann-La Roche AG New pharmaceutical formulation
EP4091614B1 (en) 2021-03-31 2023-09-06 Delta-Fly Pharma, Inc. Method for stabilizing medicinal substance sensitive to humidity (dfp-11207), and stable preparation thereof
EP4351522A1 (en) * 2021-06-09 2024-04-17 Lonza Bend Inc. Mixed solvents for spray drying for preparation of amorphous solid dispersions
WO2023069733A1 (en) * 2021-10-22 2023-04-27 Aquestive Therapeutics, Inc. Pharmaceutical compositions with enhanced stability profiles

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173811A1 (en) * 2012-05-17 2013-11-21 Genentech, Inc. Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods thereof

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040010000A1 (en) * 2002-04-29 2004-01-15 Ayer Atul D. Methods and dosage forms for controlled delivery of oxycodone
CA2393720C (en) * 2002-07-12 2010-09-14 Eli Lilly And Company Crystalline 2,5-dione-3-(1-methyl-1h-indol-3-yl)-4-[1-(pyridin-2-ylmethyl)piperidin-4-yl]-1h-indol-3-yl]-1h-pyrrole mono-hydrochloride
WO2005032525A1 (en) * 2003-10-03 2005-04-14 Lifecycle Pharma A/S A method for preparing modified release pharmaceutical compositions
KR20060108690A (ko) 2003-10-29 2006-10-18 알자 코포레이션 1일 1회 경구용의 서방성 옥시코돈 제형
US20070287719A1 (en) * 2005-03-11 2007-12-13 Pfizer Inc Salts, Prodrugs and Formulations of 1-[5-(4-Amino-7-Isopropyl-7H-Pyrrolo[2,3-D]Pyrimidine-5-Carbonyl)-2-Methoxy-Phenyl]-3-(2,4-Dichloro-Phenyl)-Urea
US20070232624A1 (en) * 2006-04-03 2007-10-04 Palumbo Joseph M Use of paliperidone for the treatment of sleep disturbances and/or excessive daytime sleepiness in psychiatric patients
US8063050B2 (en) 2006-07-06 2011-11-22 Array Biopharma Inc. Hydroxylated and methoxylated pyrimidyl cyclopentanes as AKT protein kinase inhibitors
UA95641C2 (en) 2006-07-06 2011-08-25 Эррей Биофарма Инк. Hydroxylated cyclopenta [d] pyrimidines as akt protein kinase inhibitors
CA2718330A1 (en) * 2008-04-07 2009-10-15 Chelsea Therapeutics, Inc. Antifolate compositions
KR20110105798A (ko) * 2009-01-23 2011-09-27 에프. 호프만-라 로슈 아게 알레글리타자르를 포함하는 약학 조성물
US20110086102A1 (en) * 2009-10-13 2011-04-14 Teva Pharmaceutical Industries Ltd. Delayed release compositions
TWI505828B (zh) * 2010-12-20 2015-11-01 葛蘭素史克智慧財產（第二）有限公司 新穎醫藥組成物
RU2642311C2 (ru) 2012-05-17 2018-01-24 Дженентек, Инк. Способ получения гидроксилированных циклопентапиримидиновых соединений и их солей
BR112014028589B1 (pt) 2012-05-17 2022-08-23 Genentech, Inc. Ciclopentilpirimidina hidroxilada, seu processo de fabricação e seus intermediários
CA2894153A1 (en) * 2012-12-07 2014-06-12 The General Hospital Corporation Combinations of a pi3k/akt inhibitor compound with an her3/egfr inhibitor compound and use thereof in the treatment of a hyperproliferative disorder
CN110590606B (zh) 2013-11-15 2023-02-17 豪夫迈·罗氏有限公司 用于制备嘧啶基环戊烷化合物的方法
WO2015097667A2 (en) * 2013-12-23 2015-07-02 Cellworks Group, Inc., A composition, process of preparation of said composition, kit and a method of treating cancer
JP6770946B2 (ja) 2014-07-25 2020-10-21 ノバルティス アーゲー ２−フルオロ−ｎ−メチル−４−［７−（キノリン−６−イルメチル）イミダゾ［１，２−ｂ］［１，２，４］トリアジン−２−イル］ベンズアミドの錠剤
SG11201703064WA (en) * 2014-10-23 2017-05-30 Eisai R&D Man Co Ltd Compositions and methods for treating insomnia
TWI577042B (zh) 2015-07-15 2017-04-01 南臺科技大學 發光二極體晶片及數據發射及接收裝置
JP6875501B2 (ja) 2016-08-10 2021-05-26 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト Ａｋｔプロテインキナーゼ阻害剤を含む薬学的組成物

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013173811A1 (en) * 2012-05-17 2013-11-21 Genentech, Inc. Amorphous form of an akt inhibiting pyrimidinyl - cyclopentane compound, compositions and methods thereof

Also Published As

Publication number Publication date
JP2021120376A (ja) 2021-08-19
MX2019001579A (es) 2019-06-20
KR20190038619A (ko) 2019-04-08
MX2021010041A (es) 2022-06-14
US20180055845A1 (en) 2018-03-01
US20220241279A1 (en) 2022-08-04
US11969426B2 (en) 2024-04-30
KR102281695B1 (ko) 2021-07-28
KR20210094667A (ko) 2021-07-29
US11337977B2 (en) 2022-05-24
AU2020204167B2 (en) 2021-10-21
IL264593A (en) 2019-02-28
TW202329972A (zh) 2023-08-01
JP2019524804A (ja) 2019-09-05
CN116172869A (zh) 2023-05-30
AU2017310454A1 (en) 2019-02-14
IL305639A (en) 2023-11-01
CN109789141B (zh) 2022-08-26
EP3496722A1 (en) 2019-06-19
JP6875501B2 (ja) 2021-05-26
AU2020204167A1 (en) 2020-07-09
BR112019002007B1 (pt) 2024-01-16
KR20230124110A (ko) 2023-08-24
AU2021282472B2 (en) 2024-02-22
KR102569636B1 (ko) 2023-08-23
JP2023100657A (ja) 2023-07-19
AU2021282472A1 (en) 2022-01-06
IL293480A (en) 2022-08-01
CN109789141A (zh) 2019-05-21
BR112019002007A2 (pt) 2019-05-07
IL293480B1 (en) 2023-10-01
IL264593B (en) 2022-07-01
CN115350192A (zh) 2022-11-18
AU2017310454B2 (en) 2020-06-04
CA3032233A1 (en) 2018-02-15
CA3032233C (en) 2021-09-14
WO2018029226A1 (en) 2018-02-15
TWI777658B (zh) 2022-09-11
TW201808337A (zh) 2018-03-16
TW202214299A (zh) 2022-04-16
IL293480B2 (en) 2024-02-01

Similar Documents

Publication Publication Date Title
TWI736660B (zh) 包含Akt蛋白質激酶抑制劑之醫藥組合物
JP6574417B2 (ja) 非晶質ダパグリフロジンを含有する製剤
AU2010233809B2 (en) Active pharmaceutical ingredient adsorbed on solid support
CA2940984A1 (en) Solid pharmaceutical compositions of androgen receptor antagonists
JP2005263816A (ja) 塩酸ベニジピン含有医薬組成物
JP7300725B2 (ja) 固形製剤及びその製造方法